Homepage
Medication Guide
Dosage and Administration of Sparsentan (Filspari)
Sparsentan (Filspari) is a dual antagonist of endothelin and angiotensin II receptors, which was first approved in the United States in 2023. This medication is mainly used to slow the decline of rena...
509
Tuesday, December 2nd, 2025, 09:19
What are the Indications of Sparsentan (Filspari)?
Sparsentan (Filspari) is a new type of oral medication, which was first approved for marketing in the United States in 2023. It is a dual endothelin and angiotensin II receptor antagonist, suitable fo...
508
Tuesday, December 2nd, 2025, 09:15
What Are the Purchase Channels for Sparsentan (Filspari)?
Sparsentan (Filspari) is a novel dual endothelin and angiotensin II receptor antagonist, which holds significant clinical value in delaying the decline of renal function in adult patients with primary...
509
Monday, December 1st, 2025, 11:36
Side Effects of Elacestrant (Orserdu)
Elacestrant (Orserdu) is an estrogen receptor antagonist, primarily indicated for the treatment of estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutat...
510
Monday, December 1st, 2025, 11:32
Dosage and Administration, Recommended Dose of Elacestrant (Orserdu)
Elacestrant (Orserdu) is an estrogen receptor antagonist, primarily indicated for the treatment of postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastati...
505
Monday, December 1st, 2025, 11:20
What Are the Indications of Elacestrant (Orserdu)?
Elacestrant (Orserdu) is a novel estrogen receptor antagonist. It was approved for marketing by the U.S. FDA in 2023, providing a precise treatment option for patients with advanced breast cancer harb...
507
Monday, December 1st, 2025, 11:09
What Are the Purchase Channels for Elacestrant (Orserdu)?
Elacestrant (Orserdu) is a novel estrogen receptor antagonist that plays an important role in the treatment of ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.What Are th...
509
Monday, December 1st, 2025, 10:45
Side Effects of Binimetinib (Mektovi)
Binimetinib (Mektovi) is a selective mitogen-activated protein kinase (MEK) inhibitor. It primarily blocks the RAS/RAF/MEK/ERK signaling pathway by inhibiting the activity of MEK1 and MEK2, thereby su...
508
Monday, December 1st, 2025, 10:42
What Are the Precautions for Binimetinib (Mektovi) Use?
Binimetinib (Mektovi) is a MEK inhibitor, usually used in combination with encorafenib, for the treatment of unresectable or metastatic melanoma positive for BRAF V600E or V600K mutations, as well as ...
506
Monday, December 1st, 2025, 10:38
Dosage and Administration, Recommended Dose of Binimetinib (Mektovi)
Binimetinib (Mektovi) is a kinase inhibitor, usually used in combination with encorafenib, for the treatment of unresectable or metastatic melanoma positive for BRAF V600E or V600K mutations, as well ...
507
Monday, December 1st, 2025, 10:10
47 / 214
2139 in total
Departments
Oncology Hematology Immunology Hepatology Endocrinology Pulmonology Neurology Cardiology Gastroenterology Dermatology
Contact Medical Consultant
Global Drug Search
Clinical recruitment
overseas medical treatment
Remote consultation
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Click to submit medical consultant
Contact Us
haiousales@gmail.com
Welcome To Consult
Seagull Pharmacy.,Ltd All rights reserved